Richard Greil

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

2019 | 3. lékařská fakulta, Lékařská fakulta v Hradci Králové

Publikace